Immunization with vaccines and Sjögren's syndrome

References

• Mitsias D, Moutsopoulos HM. Sjögren’s syndrome. In: Shoenfeld Y, Cervera R, Gershwin ME, editors. Diagnostic criteria in autoimmune diseases. Humana Press, Totowa, NJ 07512 USA; 2008, XIV. p.598
   Google Scholar
• Mavragani CP, Moutsopoulos HM. The geoepidemiology of Sjögren’s syndrome. Autoimmun Rev 2010;9:A305-10
   PubMed Web of Science ®Google Scholar
• Cruz-Tapias P, Rojas-Villarraga A, Maier-Moore S, Anaya JM. HLA and Sjögren’s syndrome susceptibility. A meta-analysis of worldwide studies. Autoimmun Rev 2012;11:281-7
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Busson M, Loiseau P, et al. In primary Sjögren’s syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response. Arthritis Rheum 2003;48:2240-5
   PubMedGoogle Scholar
• Tincani A, Andreoli L, Cavazzana I, et al. Novel aspects of Sjögren’s syndrome in. 2012;BMC Med 2013;11:93
   Web of Science ®Google Scholar
• Shapira Y, Agmon-Levin N, Selmi C, et al. Prevalence of anti-toxoplasma antibodies in patients with autoimmune diseases. J Autoimmun 2012;39:112-16
   PubMed Web of Science ®Google Scholar
• Sagi L, Baum S, Agmon-Levin N, et al. Autoimmune bullous diseases. The spectrum of infectious agent antibodies and review of the literature. Autoimmun Rev 2011;10:527-35
   PubMed Web of Science ®Google Scholar
• Agmon-Levin N, Shapira Y, Selmi C, et al. A comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis. J Autoimmun 2010;34:55-8
   PubMed Web of Science ®Google Scholar
• Zinger H, Sherer Y, Goddard G, et al. Common infectious agents prevalence in antiphospholipid syndrome. Lupus 2009;18:1149-53
   PubMed Web of Science ®Google Scholar
• Zandman-Goddard G, Berkun Y, Barzilai O, et al. Exposure to Epstein-Barr virus infection is associated with mild systemic lupus erythematosus disease. Ann NY Acad Sci 2009;1173:658-63
   PubMed Web of Science ®Google Scholar
• Lidar M, Langevitz P, Barzilai O, et al. Infectious serologies and autoantibodies in inflammatory bowel diseases. Insinuations at a true pathogenic role. Ann NY Acad Sci 2009;1173:640-6
   PubMed Web of Science ®Google Scholar
• Sipsas NV, Gamaletsou MN, Moutsopoulos HM. Is Sjögren syndrome a retroviral disease? Arthritis Res Ther 2011. 13:212
   Google Scholar
• Mavragani CP, Crow MK. Activation of the type I interferon pathway in primary Sjögren’s syndrome. J Autoimmun 2010;35:225-31
   PubMed Web of Science ®Google Scholar
• Talal N, Dauphinee MJ, Dang H, et al. Detection of serum autoantibodies to retroviral proteins in patients with primary Sjögren’s syndrome (autoimmune exocrinopathy). Arthritis Rheum 1990;33:774-81
   PubMed Web of Science ®Google Scholar
• Triantafyllopoulou A, Moutsopoulos HM. Autoimmunity and coxsackievirus infection in primary Sjögren’s syndrome. Ann NY Acad Sci 2005;1050:389-96
   PubMed Web of Science ®Google Scholar
• van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccinations in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011;70:414-22
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y. Agmon-Levin N. ’ASIA’ – autoimmune/ inflammatory syndrome induced by adjuvants. J Autoimmun 2011;36:4-8
   PubMed Web of Science ®Google Scholar
• Perricone C, Colafrancesco S, Mazor R, et al. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: unveiling the pathogenic, clinical and diagnostic aspects. J Autoimm 2013;47:1-16
   PubMed Web of Science ®Google Scholar
• Cruz-Tapias P, Agmon-Levin N, Israeli E, et al. Autoimmune (Auto-inflammatory) syndrome induced by adjuvants – Animal models as proof of concept. Curr Med Chem 2013;20:4030-6
   PubMed Web of Science ®Google Scholar
• Reeves WH, Lee PY, Weinstein JS, et al. Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. Trends Immunol 2009;30:455-64
   PubMed Web of Science ®Google Scholar
• Favolino E, Favia EI, Digiglio L, et al. Effects of Adjuvants for human use in systemic lupus erythematosus (Sle)-Prone (Nzb/Nzw) F1 mice. Clin Exp Immunol 2014;175(1):32-40
   PubMed Web of Science ®Google Scholar
• Eisenbarth SC, Colegio OR, O’Connor W, et al. Crucial role for the Nalp3 inflammasome in the immunostimolatory properties of aluminium adjuvants. Nature 2008;453:1122-6
   PubMed Web of Science ®Google Scholar
• Bavagant H, Nandula SR, Kaplonek P, et al. Alum, an aluminum based adjuvant, induces Sjögren’s Syndrome-like disorder in mice. Clin Exp Rheumatol 2014; In press
   Web of Science ®Google Scholar
• Guo X, Bavagant H, Brown MG, et al. Role of innate and adaptive immune responses in differential susceptibility to IFA induced Sjögren’s syndrome-like disease in NZM mouse strains. Arthritis Rheum 2006;54:s313-13
   Google Scholar
• Baldini C, Rossi C, Ferro F, et al. The P2X7 receptor-inflammasome complex has a role in modulating the inflammatory response in primary Sjögren’s syndrome. J Intern Med 2013;274:480-9
   PubMed Web of Science ®Google Scholar
• Wahren-Herlenius M, Dörner T. Immunopathogenic mechanisms of systemic autoimmune disease. Lancet 2013;382:819-31
   PubMed Web of Science ®Google Scholar
• Aimanianda V, Haensler J, Lacroix-Desmazes S, et al. Novel cellular and molecular mechanisms of induction of immune responses by aluminium adjuvants. Trends Pharmacol Sci 2009;30:287-95
   PubMed Web of Science ®Google Scholar
• De Gregorio E, D’Oro U, Wack A. Immunology of TLR-independent vaccine adjuvants. Curr Opin Immunol 2009;21:339-45
   PubMed Web of Science ®Google Scholar
• Hogenesch H. Mechanisms of immunopotentiation and safety of aluminium adjuvants. Front Immunol 2013;3:406
   PubMed Web of Science ®Google Scholar
• Marks JS, Halpin TJ. Guillain-Barré syndrome in recipients of A/New Jersey influenza vaccine. JAMA 1980;243:2490-4
   PubMed Web of Science ®Google Scholar
• Jonville-Béra AP, Autret E, Galy-Eyraud C, Hessel L. Thrombocytopenic purpura after measles, mumps and rubella vaccination: a retrospective survey by the French regional pharmacovigilance centres and Pasteur-Merieux Serums et Vaccins. Pediatr Infect Dis J 1996;15:44-8
   PubMed Web of Science ®Google Scholar
• Agmon-Levin N, Kivity S, Szyper-Kravitz M, Shoenfeld Y. Transverse myelitis and vaccines: a multi-analysis. Lupus 2009;18:1198-204
   PubMed Web of Science ®Google Scholar
• Shanklin DR, Smalley DL. Pathogenetic and diagnostic aspects of siliconosis. Rev Environ Health 2002;17:85-105
   PubMedGoogle Scholar
• Israeli E. Gulf War syndrome as a part of the autoimmune (autoinflammatory) syndrome induced by adjuvant (ASIA). Lupus 2012;21:190-4
   PubMed Web of Science ®Google Scholar
• Gherardi RK, Authier FJ. Macrophagic myofasciitis: characterization and pathophysiology. Lupus 2012;21:184-9
   PubMed Web of Science ®Google Scholar
• Rasmussen A, Ice JA, Li H, et al. Comparison of the American-European Consensus Group Sjögren’s syndrome classification criteria to newly proposed American College of Rheumatology criteria in a large, carefully, characterized sicca cohort. Ann Rheum Dis 2014;73:31-8
   PubMed Web of Science ®Google Scholar
• Jonsson R, Theander E, Sjöström B, Brokstad K, Henriksson G. Autoantibodies present before symptom onset in primary Sjögren syndrome. JAMA 2013 Nov 6;310(17):1854-5
   PubMed Web of Science ®Google Scholar
• Toussirot E, Bossert M, Herbein G, Saas P. Comments on the article by Tabache F et al. ‘Acute polyarthritis after influenza A H1N1 immunization’, Joint Bone Spine 2011, doi:10.1016/j.jbs.2011.02.007: primary Sjögren’s syndrome occurring after influenza A H1N1 vaccine administration. Joint Bone Spine 2012;79:107
   PubMed Web of Science ®Google Scholar
• Toussirot E, Lohse A, Wendling D, Mougin C. Sjögren syndrome occurring after hepatitis B vaccination. Arthritis Rheum 2000;43:2139-40
   PubMedGoogle Scholar
• Narvàez J, Castro-Bohorquez FJ, Vilaseca-Momplet J. Sjögren’s like syndrome following intravescical bacillus Calmette-Guérin immunotherapy. Am J Med 2003;115:418-20
   PubMed Web of Science ®Google Scholar
• Cherif H, Hoglund M, Pauksens K. Adjuvanted influenza a (H1N1) 2009 vaccine in patients with hematological diseases: good safety and immunogenicity even in chemotherapy-treated patients. Eur J Haematol 2013;90:413-19
   PubMed Web of Science ®Google Scholar
• Touma Z, Gladman DD, Urowitz MB. Vaccination and auto-immune rheumatic diseases: lessons learnt from the 2009 H1N1 influenza virus vaccination campaign. Curr Opin Rheumatol 2013;25:164-70
   PubMed Web of Science ®Google Scholar
• Stubgen JP. Neuromuscular disorders associated with Hepatitis B vaccination. J Neurol Sci 2010;292:1-4
   PubMed Web of Science ®Google Scholar
• Evans D, Cauchemez S, Hayden FG. ‘Prepandemic’ immunization for novel influenza viruses, ‘swine flu’ vaccine, Guillain-Barré syndrome, and the detection of rare severe adverse events. J Infect Dis 2009;200:321-8
   PubMed Web of Science ®Google Scholar
• Mikaeloff Y, Caricade G, Suissa S, Tardieu M. Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood. Neurology 2009;72:873-80
   PubMed Web of Science ®Google Scholar
• Zafrir Y, Agmon-Levin N, Paz Z, et al. Autoimmunity following Hepatitis B vaccine as part of the spectrum of ‘Autoimmune (Auto-inflammatory) syndrome induced by adjuvants’ (ASIA): analysis of 93 cases. Lupus 2012;21:146-52
   PubMed Web of Science ®Google Scholar
• Nakamura T, Yamamura J, Sato H, et al. Vasculitis induced by immunization with Bacillus Calmette-Guérin followed by atypical mycobacterium antigen: a new mouse model for Kawasaki disease. FEMS Immunol Med Microbiol 2007;49:391-7
   PubMedGoogle Scholar
• Raheem OA, Kalunian K, Kellogg Parsons J. Acute arthritis secondary to intravescical bacillus Calmette-Guérin for bladder cancer. Actas Urol Esp 2012;36:461-6
   PubMed Web of Science ®Google Scholar
• Alijotas-Reig J, Fernandez-Figueras M, Puig L. Late onset inflammatory adverse reactions related to soft tissue filler injections. Clin Rev Allergy Immunol 2013;45:97-108
   PubMed Web of Science ®Google Scholar
• van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune rheumatic diseases. Ann Rheum Dis 2011;70:414-22
   PubMed Web of Science ®Google Scholar
• Saad CG, Borba EF, Aikawa NE, et al. Immunogenity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases. Ann Rheum Dis 2011;70:1068-73
   PubMed Web of Science ®Google Scholar
• Kostianovsky A, Charles P, Alves JF, et al. Immunogenity and safety of seasonal and 2009 pandemic A/H1N1 influenza vaccines for patients with autoimmune diseases: a prospective, monocentre trial on 199 patients. Clin Exp Rheumatol 2012;30:S83-9
   PubMed Web of Science ®Google Scholar
• Müller-Ladner C, Müller-Ladner U. Vaccinations and inflammatory arthritis: overview of current vaccines and recommended uses in rheumatology. Curr Rheumatol Rep 2013;15:330
   PubMed Web of Science ®Google Scholar
• Pasoto SG, Ribeiro AC, Viana VS, et al. Short and long-term effects of pandemic unadjuvanted influenza A(H1N1) pdm09 vaccine on clinical manifestations and autoantibody profile in primary Sjögren syndrome. Vaccine 2013;31:1793-8
   PubMed Web of Science ®Google Scholar
• Milanovic M, Stojanovic L, Djokovic A, et al. Influenza vaccination in autoimmune rheumatic disease patients. Tohoku J Exp Med 2013;229:29-34
   PubMed Web of Science ®Google Scholar